GO:1990265 platelet-derived growth factor complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990265 (platelet-derived growth factor complex) is a cellular_component term describing secreted disulfide-linked dimers of PDGF A, B, C, or D chains that exist as five isoforms: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD.
• PDGF dimers bind and dimerize PDGF receptors (PDGFRA/PDGFRB) at the plasma membrane, activating downstream signaling that drives fibroblast, smooth muscle, and pericyte proliferation and migration.
• PDGF-AA secreted by senescent cells is required for optimal wound healing, establishing the complex as a key paracrine mediator of tissue repair.
• PDGF-BB and PDGF-DD are strongly implicated in vascular calcification, fibrosis, and tumor-stroma crosstalk, including cholangiocarcinoma and gastrointestinal stromal tumors.
• PDGF-C and PDGF-D, the newer members of the family, are emerging therapeutic targets in triple-negative breast cancer and other malignancies.
• CRISPR knockout, knock-in, and overexpression models of PDGFA, PDGFB, PDGFC, and PDGFD enable causal dissection of each dimer's role in health and disease.
Description
The platelet-derived growth factor complex (GO:1990265) is a secreted protein complex composed of two PDGF subunit chains that assemble into disulfide-linked dimers. In vertebrates, four PDGF chains (A, B, C, and D) generate five biologically distinct dimers: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. These dimers act as extracellular ligands that bind to and dimerize PDGF receptors on the plasma membrane, initiating intracellular signaling cascades that control cell proliferation, migration, and survival. Because PDGF signaling is central to wound healing, angiogenesis, and tissue remodeling, the complex is a focal point for research in regenerative biology and oncology. The PDGF complex is not a single static entity but a family of dimeric ligands with overlapping and distinct receptor specificities. PDGF-AA, AB, and BB are the classic isoforms, while PDGF-CC and PDGF-DD were identified later and require proteolytic activation. This diversity allows fine-tuned regulation of mesenchymal cell behavior in different physiological contexts, from embryonic development to adult tissue homeostasis. For researchers, GO:1990265 provides a precise annotation for experimental models that manipulate PDGF ligand production, secretion, or dimerization. Understanding the complex's composition and assembly is essential for interpreting knockout, knock-in, and overexpression phenotypes, and for designing targeted therapeutics in fibrosis, vascular disease, and cancer.
platelet-derived growth factor complex At A Glance
| GO ID | GO:1990265 |
|---|---|
| GO term | platelet-derived growth factor complex |
| Ontology | cellular_component |
| Synonym | PDGF-AA dimer; PDGF-AB dimer; PDGF-BB dimer; PDGF-CC dimer; PDGF-DD dimer; PDGF complex |
| Major function | Secreted dimeric ligand that binds and activates PDGF receptors to drive cell proliferation, migration, and survival |
| Subunit composition | Two PDGF chains selected from A, B, C, and D, forming five dimers (AA, AB, BB, CC, DD) |
| Cellular localization | Secreted extracellular space; binds to plasma membrane PDGF receptors |
| Taxonomic range | All vertebrates; four chains in mammals |
| Associated processes | Wound healing, vascular calcification, tumor-stroma crosstalk, fibrosis |
What Is GO:1990265?
GO:1990265 defines the platelet-derived growth factor complex as a protein complex consisting of two chains of PDGF subunits. These dimers bind to PDGF receptors in the plasma membrane, inducing receptor dimerization and activation. PDGFs participate in a wide variety of signaling processes and are found in all vertebrates, where at least two different chains (A and B) exist. In humans and other mammals, four PDGF chains (A, B, C, and D) form five different dimers: AA, AB, BB, CC, and DD.
Why Is platelet-derived growth factor complex Important in Cell Biology?
The platelet-derived growth factor complex is a master regulator of mesenchymal cell biology, and its dysregulation is causally linked to major human diseases including fibrosis, vascular calcification, and multiple cancers. Because PDGF dimers are secreted ligands, they represent accessible therapeutic targets and biomarkers, and their study requires precise genetic models to distinguish the roles of each dimer.
• PDGF-AA secreted by senescent cells is essential for optimal wound healing, linking the complex to tissue repair and aging.
• PDGF-BB and PDGF-DD promote vascular calcification, a major contributor to cardiovascular morbidity.
• PDGF signaling is a hallmark of fibrosis in multiple organs, including liver and lung.
• PDGF-C and PDGF-D are overexpressed in triple-negative breast cancer and contribute to chemoresistance.
• Gastrointestinal stromal tumors frequently depend on PDGF receptor signaling, making the complex a therapeutic target.
• PDGF-CC and PDGF-DD require proteolytic activation, adding a layer of regulation that can be exploited pharmacologically.
• The complex is a model system for studying secreted growth factor assembly and receptor tyrosine kinase activation.
• CRISPR-based models of PDGF ligands enable causal testing of each dimer in disease.
• PDGF dimers are used in regenerative medicine, including hydrogel-based delivery for chronic wounds.
• Understanding PDGF complex biology informs the development of isoform-selective inhibitors.
Structure and Composition of platelet-derived growth factor complex
PDGF chain diversity and dimer assembly
In simple terms: Four different PDGF protein chains can pair up in different combinations to form five distinct growth factor dimers.
The PDGF complex is built from four gene products: PDGFA, PDGFB, PDGFC, and PDGFD. Each chain contains a conserved cystine-knot growth factor domain that mediates disulfide-linked dimerization. The chains assemble in the endoplasmic reticulum and are secreted as dimers: PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD. The A and B chains are the classic isoforms, while C and D are synthesized as latent forms requiring extracellular proteolysis for activation.
Receptor binding and activation
In simple terms: The PDGF dimer binds to two receptor molecules on the cell surface, pulling them together and switching on their signaling activity.
Secreted PDGF dimers bind to two related receptor tyrosine kinases, PDGFRA and PDGFRB, on the plasma membrane. Binding induces receptor dimerization and autophosphorylation, which creates docking sites for downstream signaling proteins. Different PDGF dimers have distinct receptor preferences: PDGF-AA binds PDGFRA, PDGF-BB binds both PDGFRA and PDGFRB, and PDGF-CC and PDGF-DD primarily activate PDGFRA and PDGFRB, respectively.
Proteolytic activation of PDGF-C and PDGF-D
In simple terms: PDGF-C and PDGF-D are made as inactive precursors that must be cut by enzymes before they can bind receptors.
PDGFC and PDGFD are secreted as latent dimers containing an N-terminal CUB domain that must be removed by extracellular proteases to release the active growth factor domain. This proteolytic step provides an additional layer of regulation and is often dysregulated in cancer and fibrosis, making it a potential therapeutic target.
Extracellular matrix interactions
In simple terms: PDGF dimers can stick to the matrix around cells, which controls how far they travel and how long they signal.
PDGF dimers interact with extracellular matrix components such as heparan sulfate proteoglycans, which modulate their bioavailability and signaling range. This interaction is important for localized wound healing responses and for creating gradients that guide cell migration.
Key Genes Involved in GO:1990265 platelet-derived growth factor complex
The following genes encode the PDGF chains, receptors, and key regulatory proteins that define the platelet-derived growth factor complex and its signaling network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDGFA | Encodes PDGF-A chain; forms PDGF-AA and PDGF-AB dimers | Senescent cell secretome; wound healing; fibrosis models |
| PDGFB | Encodes PDGF-B chain; forms PDGF-AB and PDGF-BB dimers | Vascular development; pericyte recruitment; GIST biology |
| PDGFC | Encodes PDGF-C chain; forms PDGF-CC dimer | Triple-negative breast cancer; cholangiocarcinoma stroma |
| PDGFD | Encodes PDGF-D chain; forms PDGF-DD dimer | Vascular calcification; cancer-associated fibroblasts |
| PDGFRA | Encodes PDGF receptor alpha; binds PDGF-AA, AB, BB, CC | Receptor activation studies; GIST subtypes |
| PDGFRB | Encodes PDGF receptor beta; binds PDGF-BB and PDGF-DD | Vascular calcification; pericyte signaling |
| FURIN | Protease that activates PDGF-C and PDGF-D precursors | Regulation of latent PDGF dimer activation |
| PLAT | Tissue plasminogen activator; can proteolytically activate PDGF-C | Extracellular proteolysis of PDGF complexes |
| MMP2 | Matrix metalloproteinase; contributes to PDGF-C activation | Matrix remodeling and PDGF bioavailability |
| MMP9 | Matrix metalloproteinase; modulates PDGF signaling | Wound healing and tumor microenvironment |
| SPP1 | Osteopontin; interacts with PDGF signaling in calcification | Vascular calcification models |
| COL1A1 | Collagen type I; downstream of PDGF in fibrosis | Fibrosis and wound healing readouts |
| ACTA2 | Alpha smooth muscle actin; marker of PDGF-driven myofibroblasts | Fibrosis and vascular remodeling |
| CDKN2A | p16; senescence marker linked to PDGF-AA secretion | Senescent cell biology in wound healing |
| TP53 | Tumor suppressor; mutated in cancers with PDGF signaling | Cancer models with PDGF-driven stroma |
| VEGFA | Vascular endothelial growth factor; crosstalk with PDGF in angiogenesis | Angiogenesis and wound healing studies |
| HIF1A | Hypoxia-inducible factor; regulates PDGF expression | Hypoxic tumor microenvironment |
| TGFB1 | Transforming growth factor beta; synergizes with PDGF in fibrosis | Combined growth factor signaling models |
How Is platelet-derived growth factor complex Regulated?
PDGF complex activity is regulated at multiple levels: transcriptionally by hypoxia and growth factors, post-translationally by proteolytic activation of PDGF-C and PDGF-D, and extracellularly by matrix binding and receptor availability. In wound healing, senescent cells transiently secrete PDGF-AA, and this secretion is tightly controlled to avoid fibrosis. In cancer, PDGF ligands are often upregulated by tumor cells and stromal cells, creating autocrine and paracrine loops that sustain proliferation and chemoresistance. Receptor levels and downstream signaling components further modulate the intensity and duration of PDGF complex signaling.
platelet-derived growth factor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDGFA | Wound healing; senescence-associated repair | PDGFA knockout mice; senescent cell co-culture |
| PDGFB | Vascular calcification; GIST | PDGFB overexpression in smooth muscle cells; GIST cell lines |
| PDGFC | Triple-negative breast cancer; cholangiocarcinoma | PDGFC knockout or knockdown in cancer cells; xenografts |
| PDGFD | Vascular calcification; cancer-associated fibroblasts | PDGFD knockout mice; fibroblast activation assays |
| PDGFRA | Gastrointestinal stromal tumors | PDGFRA mutant knock-in models; imatinib response studies |
PDGF complex in cancer and tumor stroma
PDGF dimers, particularly PDGF-BB, PDGF-CC, and PDGF-DD, are overexpressed in multiple cancers and drive tumor growth, angiogenesis, and recruitment of cancer-associated fibroblasts. In cholangiocarcinoma, PDGF-D mediates crosstalk between tumor cells and stromal fibroblasts, promoting a pro-tumorigenic microenvironment. In triple-negative breast cancer, inhibition of PDGF-C and its receptors enhances the effects of doxorubicin, suggesting that PDGF complex signaling contributes to chemoresistance. Gastrointestinal stromal tumors often depend on PDGF receptor signaling, and PDGF ligands can contribute to tumor progression.
PDGF complex in vascular calcification and cardiovascular disease
PDGF-BB and PDGF-DD promote vascular smooth muscle cell phenotypic switching and calcification, a process that underlies atherosclerosis and arterial stiffness. The complex activates signaling pathways that induce osteogenic differentiation of vascular cells, and targeting PDGF signaling reduces calcification in preclinical models.
PDGF complex in wound healing and fibrosis
PDGF-AA secreted by senescent cells is required for optimal wound healing, and its absence delays tissue repair. However, excessive or prolonged PDGF signaling contributes to fibrosis in the liver, lung, and kidney, where PDGF dimers stimulate myofibroblast proliferation and collagen deposition. Controlled delivery of PDGF via hydrogels has been explored to accelerate chronic wound healing.
From platelet-derived growth factor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PDGFA loss impair wound healing? | PDGFA knockout mice or CRISPR knockout in fibroblasts |
| Does PDGF-BB drive vascular calcification? | PDGFB overexpression in vascular smooth muscle cells |
| Is PDGF-C required for breast cancer chemoresistance? | PDGFC knockout in triple-negative breast cancer cells |
| How does PDGF-DD activate fibroblasts? | PDGFD knock-in with tagged version for tracking |
| Which PDGF dimer activates PDGFRA vs PDGFRB? | Point mutations in receptor binding domains; knock-in models |
| Can PDGF-AA delivery accelerate chronic wound healing? | Hydrogel-based PDGF-AA delivery in wound models |
How to Study the platelet-derived growth factor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of specific PDGF chain expression | Causal testing of PDGFA/B/C/D in disease models |
| Western blot (non-reducing) | PDGF dimer size and composition | Confirming dimer formation in cells |
| Receptor phosphorylation assay | PDGF receptor activation | Testing dimer-specific receptor activation |
| Proliferation/migration assay | Cellular response to PDGF dimers | Functional readout of PDGF complex activity |
| Immunohistochemistry | PDGF ligand and receptor localization in tissue | Wound healing and tumor stroma analysis |
| Mass spectrometry | Identification of PDGF dimer species | Biochemical characterization of secreted complexes |
| Hydrogel delivery | Controlled release of PDGF dimers | Chronic wound healing applications |
| Xenograft tumor models | Tumor growth and stroma interactions | Testing PDGF-C/D inhibition in cancer |
Genetic knockout and knockdown
CRISPR-Cas9 knockout of PDGFA, PDGFB, PDGFC, or PDGFD in cell lines and animal models allows causal testing of each dimer's function. Knockout of PDGFA in senescent cells demonstrated its essential role in wound healing. Knockdown of PDGFC in breast cancer cells increased doxorubicin sensitivity.
Receptor activation and signaling assays
PDGF complex activity is measured by receptor autophosphorylation, downstream AKT and ERK phosphorylation, and proliferation or migration assays. These assays can be performed with recombinant PDGF dimers or conditioned medium from cells expressing specific PDGF chains.
Proteomic and biochemical analysis of dimers
Immunoprecipitation, Western blotting under non-reducing conditions, and mass spectrometry can resolve the dimeric composition of PDGF complexes in biological samples. These methods are essential for confirming which dimers are produced by a given cell type.
In vivo wound healing and disease models
Excisional wound models, vascular calcification models, and tumor xenografts are used to study PDGF complex function in vivo. Hydrogel delivery systems provide controlled release of specific PDGF dimers to test therapeutic potential.
How CRISPR Can Be Used to Study GO:1990265 platelet-derived growth factor complex
Knockout
CRISPR knockout of PDGFA, PDGFB, PDGFC, or PDGFD eliminates specific PDGF chains, preventing formation of dimers containing that chain. This approach has been used to show that PDGF-AA from senescent cells is required for optimal wound healing and that PDGF-C inhibition increases doxorubicin sensitivity in breast cancer. Knockout models are essential for distinguishing the roles of individual dimers.
Point Mutation
Point mutations can be introduced into PDGF chain genes to disrupt receptor binding interfaces or proteolytic cleavage sites. For example, mutating the CUB domain cleavage site in PDGF-C prevents its activation, allowing researchers to study the latent form. Point mutations in PDGFRA or PDGFRB can model resistance to kinase inhibitors in GIST.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins into PDGF chain genes enables tracking of dimer secretion and localization. Knock-in of disease-associated mutations, such as those in PDGFRA found in GIST, creates isogenic models for drug testing. Knock-in of human PDGF genes into mouse models can humanize the PDGF complex for therapeutic studies.
Overexpression
Overexpression of PDGF chains via CRISPR activation or lentiviral delivery increases specific dimer levels, mimicking pathological states such as fibrosis or cancer. Overexpression of PDGF-BB in vascular smooth muscle cells drives calcification, and PDGF-D overexpression promotes fibroblast activation. These models are useful for testing inhibitors and studying downstream signaling.
How EDITGENE Supports platelet-derived growth factor complex Research
Researchers studying platelet-derived growth factor complex-related genes often need to determine whether a candidate gene is causally involved in dimer assembly, secretion, or downstream signaling. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for platelet-derived growth factor complex research.
Frequently Asked Questions About platelet-derived growth factor complex
What is GO:1990265?
GO:1990265 is the Gene Ontology cellular_component term for platelet-derived growth factor complex, a secreted dimer of two PDGF chains that binds and activates PDGF receptors.
What genes are involved in platelet-derived growth factor complex?
The complex is formed by PDGFA, PDGFB, PDGFC, and PDGFD, which produce five dimers (AA, AB, BB, CC, DD) that signal through PDGFRA and PDGFRB.
What are the five PDGF dimers?
The five dimers are PDGF-AA, PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD, each with distinct receptor binding preferences and biological roles.
How does the PDGF complex activate signaling?
PDGF dimers bind to PDGF receptors on the plasma membrane, inducing receptor dimerization and autophosphorylation, which triggers downstream pathways like PI3K/AKT and MAPK.
What diseases are associated with PDGF complex dysfunction?
PDGF complex dysfunction is linked to cancer, vascular calcification, fibrosis, and impaired wound healing.
What is the role of PDGF-AA in wound healing?
PDGF-AA secreted by senescent cells is required for optimal wound healing, and its loss delays tissue repair.
How is PDGF-C activated?
PDGF-C is secreted as a latent dimer that requires proteolytic removal of its CUB domain by extracellular proteases to become active.
Can CRISPR be used to study PDGF complex genes?
Yes, CRISPR knockout, knock-in, and overexpression models enable precise manipulation of PDGFA, PDGFB, PDGFC, and PDGFD to study their roles in disease.
What is the difference between PDGF-CC and PDGF-DD?
PDGF-CC and PDGF-DD are newer PDGF dimers that require proteolytic activation and primarily signal through PDGFRA and PDGFRB, respectively.
Why is the PDGF complex important in cancer?
PDGF dimers promote tumor growth, angiogenesis, and chemoresistance by acting on cancer cells and the tumor stroma, making them therapeutic targets.
Conclusion
The platelet-derived growth factor complex (GO:1990265) is a central secreted signaling module that controls mesenchymal cell behavior in development, tissue repair, and disease. Its five dimeric isoforms, encoded by PDGFA, PDGFB, PDGFC, and PDGFD, provide a versatile system for paracrine and autocrine signaling through PDGF receptors. Dysregulation of the complex contributes to cancer, vascular calcification, and fibrosis, while controlled PDGF-AA delivery supports wound healing. CRISPR-based models are indispensable for dissecting the specific roles of each PDGF dimer and for developing targeted therapies. EDITGENE's knockout, knock-in, overexpression, and screening services empower researchers to generate publication-ready data on PDGF complex biology and its therapeutic potential.
References
- 1. Demaria M et al.. 2014. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA.. Dev Cell 31(6):722-33 PMID: 25499914
- 2. Ouyang L et al.. 2018. Roles of platelet-derived growth factor in vascular calcification.. J Cell Physiol 233(4):2804-2814 PMID: 28467642
- 3. Kaltalioglu K et al.. 2015. A bioactive molecule in a complex wound healing process: platelet-derived growth factor.. Int J Dermatol 54(8):972-7 PMID: 25312059
- 4. Khachigian LM et al.. 1992. Platelet-derived growth factor and alternative splicing: a review.. Pathology 24(4):280-90 PMID: 1289770
- 5. Berasain C et al.. 2013. Platelet-derived growth factor D: a new player in the complex cross-talk between cholangiocarcinoma cells and cancer-associated fibroblasts.. Hepatology 58(3):853-5 PMID: 23696149
- 6. Qin X et al.. 2025. Controlled platelet-derived growth factor delivery by hyaluronic acid hydrogels with tunable crosslinking for accelerated chronic wound healing.. Int J Biol Macromol 304(Pt 1):140710 PMID: 39920953
- 7. Kim S et al.. 2021. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells.. Eur J Pharmacol 895:173868 PMID: 33460613
- 8. Miettinen M et al.. 2013. Gastrointestinal stromal tumors.. Gastroenterol Clin North Am 42(2):399-415 PMID: 23639648
